Format

Send to

Choose Destination
Br J Surg. 2015 Jul;102(8):894-901. doi: 10.1002/bjs.9824. Epub 2015 May 12.

Randomized clinical trial of mast cell inhibition in patients with a medium-sized abdominal aortic aneurysm.

Author information

1
Department of Vascular Surgery, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
2
Department of Cardiothoracic and Vascular Surgery T, Aarhus University Hospital Skejby, Aarhus, Denmark.
3
Department of Vascular Surgery, Karolinska University Hospital, Stockholm, Sweden.
4
Department of Vascular and Transplantation Surgery K6-R, Leiden University Medical Centre, Leiden, The Netherlands.
5
St George's Vascular Institute, St George's University Hospital, London, UK.
6
Department of Vascular Surgery, Institution of Surgical Science, Uppsala University Hospital, Uppsala, Sweden.
7
Department of Vascular Surgery, Sahlgrenska University Hospital, University of Gotheborg, Gotheborg, Sweden.

Abstract

BACKGROUND:

Abdominal aortic aneurysm (AAA) is thought to develop as a result of inflammatory processes in the aortic wall. In particular, mast cells are believed to play a central role. The AORTA trial was undertaken to investigate whether the mast cell inhibitor, pemirolast, could retard the growth of medium-sized AAAs. In preclinical and clinical trials, pemirolast has been shown to inhibit antigen-induced allergic reactions.

METHODS:

Inclusion criteria for the trial were patients with an AAA of 39-49 mm in diameter on ultrasound imaging. Among exclusion criteria were previous aortic surgery, diabetes mellitus, and severe concomitant disease with a life expectancy of less than 2 years. Included patients were treated with 10, 25 or 40 mg pemirolast, or matching placebo for 52 weeks. The primary endpoint was change in aortic diameter as measured from leading edge adventitia at the anterior wall to leading edge adventitia at the posterior wall in systole. All ultrasound scans were read in a central imaging laboratory.

RESULTS:

Some 326 patients (mean age 70·8 years; 88·0 per cent men) were included in the trial. The overall mean growth rate was 2·42 mm during the 12-month study. There was no statistically significant difference in growth between patients receiving placebo and those in the three dose groups of pemirolast. Similarly, there were no differences in adverse events.

CONCLUSION:

Treatment with pemirolast did not retard the growth of medium-sized AAAs.

REGISTRATION NUMBER:

NCT01354184 (https://www.clinicaltrials.gov).

PMID:
25963302
DOI:
10.1002/bjs.9824
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center